This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study
by Zacks Equity Research
Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer.
Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMV
Is Nuveen ESG Large-Cap Value ETF (NULV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NULV
FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug
by Zacks Equity Research
The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.
AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal
by Zacks Equity Research
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.
Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults
by Zacks Equity Research
Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.
PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study
by Zacks Equity Research
PDS Biotech's (PDSB) shares gain as it announces encouraging interim data from the VERSATILE-002 study for treating HPV16-positive cancer patients.
Immutep (IMMP) Up on Initial Data From Lung Cancer Study
by Zacks Equity Research
Immutep (IMMP) shares surge on encouraging initial data from a triple combination therapy study, INSIGHT-003, for non-small cell lung cancer.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study
by Zacks Equity Research
PDS Biotech (PDSB) shares gain as it completes patient enrollment in the second arm of the VERSATILE-002 study for treating HPV16-positive cancer patients.
Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data
by Zacks Equity Research
A mid-stage study data shows that Immutep's (IMMP) lead candidate as a combination therapy in first-line NSCLC achieved better-than-expected overall survival results.
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why
by Zacks Equity Research
Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.
The Zacks Analyst Blog Highlights UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International
by Zacks Equity Research
UnitedHealth Group, Merck, Texas Instruments, The TJX Companies and Johnson Controls International are part of the Zacks top Analyst Blog.
Top Research Reports for UnitedHealth Group, Merck & Texas Instruments
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Merck & Co., Inc. (MRK) and Texas Instruments Incorporated (TXN).
Should ALPS O'Shares U.S. Quality Dividend ETF (OUSA) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for OUSA
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.
Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up
by Zacks Equity Research
Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.
Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance
by Zacks Equity Research
Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.
Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%
by Zacks Equity Research
Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study
by Kinjel Shah
Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.
Seagen's (SGEN) Q1 Earnings and Revenues Miss Expectations
by Zacks Equity Research
Seagen (SGEN) reports worse-than-expected results in the first quarter of 2023, missing both earnings and sales estimates.